4
Changes in Ownership
Beam Therapeutics Inc. Filed Acc 0000899243-21-033848
CEO sold 20,000 shares at an average $99.49 ($1,989,744)
- CEO acquired 12,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Evans John M. CEO | 2021-08-19 | Sale | −400 | $96.38 | $38,552 | 222,600 | I |
| Evans John M. CEO | 2021-08-19 | Sale | −1,000 | $97.50 | $97,500 | 221,600 | I |
| Evans John M. CEO | 2021-08-19 | Sale | −3,140 | $98.74 | $310,044 | 218,460 | I |
| Evans John M. CEO | 2021-08-19 | Sale | −9,704 | $99.53 | $965,839 | 208,756 | I |
| Evans John M. CEO | 2021-08-19 | Sale | −5,456 | $100.35 | $547,510 | 203,300 | I |
| Evans John M. CEO | 2021-08-19 | Sale | −300 | $101.00 | $30,300 | 203,000 | I |
| Evans John M. CEO | 2021-08-19 | Option exercise | +12,000 | $1.03 | $12,360 | 1,033,525 | D |
| Derivatives | |||||||
| Evans John M. CEO | 2021-08-19 | Option exercise · Stock Option (Right to Buy) | −12,000 | 359,345 | D | ||
| Open-market sales · 20,000 sh · avg $99.49 · $1,989,744 | |||||||
Loading xslF345X03/doc4.xml…